Kadmon Holdings Inc (NASDAQ:KDMN) Receives Consensus Rating of “Buy” from Analysts

Shares of Kadmon Holdings Inc (NASDAQ:KDMN) have been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.92.

Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Kadmon Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Piper Jaffray Companies restated a “buy” rating and issued a $7.00 price target on shares of Kadmon Holdings in a research note on Friday, July 14th. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Kadmon Holdings in a research note on Monday, June 26th. Finally, Citigroup Inc. reduced their price objective on shares of Kadmon Holdings from $6.00 to $4.00 and set a “neutral” rating on the stock in a research note on Monday, March 27th.

Kadmon Holdings (NASDAQ KDMN) traded down 4.33% on Monday, hitting $2.87. 88,899 shares of the stock were exchanged. The stock’s market capitalization is $148.80 million. The company has a 50 day moving average of $3.18 and a 200 day moving average of $3.43. Kadmon Holdings has a one year low of $2.25 and a one year high of $11.73.

Kadmon Holdings (NASDAQ:KDMN) last released its quarterly earnings results on Monday, May 15th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.13. The business had revenue of $5.60 million during the quarter, compared to analyst estimates of $4.25 million. The business’s revenue was down 42.3% compared to the same quarter last year. On average, equities research analysts forecast that Kadmon Holdings will post ($1.67) earnings per share for the current fiscal year.

In other news, major shareholder Goldentree Asset Management Lp sold 515,643 shares of the firm’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $3.51, for a total value of $1,809,906.93. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 1,490,670 shares of company stock worth $5,284,489.

Several large investors have recently bought and sold shares of the stock. Macquarie Group Ltd. bought a new stake in Kadmon Holdings during the fourth quarter worth $2,696,000. Nationwide Fund Advisors bought a new stake in Kadmon Holdings during the first quarter worth $192,000. Wells Fargo & Company MN increased its stake in Kadmon Holdings by 84.8% in the first quarter. Wells Fargo & Company MN now owns 51,291 shares of the company’s stock worth $186,000 after buying an additional 23,541 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Kadmon Holdings by 302.3% in the first quarter. Bank of New York Mellon Corp now owns 46,304 shares of the company’s stock worth $167,000 after buying an additional 34,794 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Kadmon Holdings by 11,654.8% in the first quarter. JPMorgan Chase & Co. now owns 228,866 shares of the company’s stock worth $829,000 after buying an additional 226,919 shares during the last quarter.

WARNING: This piece of content was originally published by [[site]] and is the sole property of of [[site]]. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at [[permalink]].

About Kadmon Holdings

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.